AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.
CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.
IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.
IonQ shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca, Amazon Web Services and Nvidia.
An investment management firm known for short-selling the stocks it speaks against is now targeting a high-risk, high-reward stock purchased by a high-profile politician.
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.
